Transgenic overexpression of human Bcl-2 in islet β cells inhibits apoptosis but does not prevent autoimmune destruction

Janette Allison, Helen Thomas, Dianne Beck, Jamie L. Brady, Andrew M. Lew, Andrew Elefanty, Hiro Kosaka, Thomas W. Kay, David C.S. Huang, Andreas Strasser

Research output: Contribution to journalArticleResearchpeer-review

57 Citations (Scopus)

Abstract

Insulin-dependent diabetes mellitus results when > 90% of the insulin-producing β cells in the pancreatic islets are killed as a result of autoimmune attack by T cells. During the progression to diabetes, islet β cells die as a result of different insults from the immune system. Agents such as perforin and granzymes, CD95 ligand and tumor necrosis factor-α, or cytokines and free-radicals have all been shown to cause β cell apoptosis. The anti-apoptotic protein, Bcl-2, might protect against some of these stimuli. We have therefore generated transgenic mice expressing human Bcl-2 in their islet β cells. Although Bcl-2 was able to prevent apoptosis induced by cytotoxic agents against β cells in vitro, Bcl-2 alone could not prevent or ameliorate cytotoxic or autoimmune β cell damage in vivo.

Original languageEnglish
Article number0120009
Pages (from-to)9-17
Number of pages9
JournalInternational Immunology
Volume12
Issue number1
DOIs
Publication statusPublished - 1 Jan 2000
Externally publishedYes

Keywords

  • Insulin-dependent diabetes mellitus
  • Non-obese diabetic mouse
  • β cell death

Cite this